Exciting new advances in detection and treatment
As the second biggest cause of cancer deaths in Australian men, prostate cancer has been the focus of intensive research in this country, including at the University of Adelaide. Pleasingly, big strides are being made.
Novel early detection tests are being developed to differentiate between lethal and non-lethal tumours. Improved lab models aim to increase the accuracy of new drug performance predictions. Moreover, a greater understanding of hormone action promises to help restrict the growth of advanced tumours.
New agents are also emerging to enhance the treatment of metastatic prostate cancer, with expectations high of improving both patient survival and comfort.
In this detailed presentation some of our leading researchers will explain how these exciting steps are being taken and, where possible, when patients might hope to start benefitting from them.
The speakers
Dr Lisa Butler is Deputy Director of the University’s Dame Roma Mitchell Cancer Research Laboratories and leads its Molecular Therapeutics group.
Dr Luke Selth is a Research Fellow within the University’s Dame Roma Mitchell Cancer Research Laboratories.
Dr Peter Sutherland MBBS, FRACS, is Head of Urology at the Royal Adelaide Hospital and initiated its Da Vinci Robotic Surgery Program for prostate cancer. He regularly collaborates with the University’s Dame Roma Mitchell Cancer Research Laboratories.
Dr Francis Parnis MBBS, FRACP, is a medical oncologist at, and co-founder of, the Adelaide Cancer Centre. He currently runs clinical trials for the latest prostate cancer therapies.
